 Augusto Miravalle
Concepts (87)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 9 | 2021 | 372 | 1.270 |
Why?
| | Immunosuppressive Agents | 5 | 2021 | 641 | 1.190 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 5 | 2021 | 69 | 1.160 |
Why?
| | Nervous System Diseases | 3 | 2015 | 254 | 1.040 |
Why?
| | Cladribine | 1 | 2021 | 2 | 0.740 |
Why?
| | Vaccines | 2 | 2014 | 375 | 0.550 |
Why?
| | Encephalomyelitis, Acute Disseminated | 2 | 2009 | 13 | 0.550 |
Why?
| | Demyelinating Diseases | 2 | 2019 | 73 | 0.540 |
Why?
| | Clinical Coding | 1 | 2016 | 19 | 0.530 |
Why?
| | Office Visits | 1 | 2016 | 79 | 0.520 |
Why?
| | International Classification of Diseases | 1 | 2016 | 116 | 0.500 |
Why?
| | Immunologic Factors | 5 | 2020 | 217 | 0.470 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 2 | 2012 | 18 | 0.460 |
Why?
| | Vaccination | 2 | 2014 | 1202 | 0.450 |
Why?
| | Natalizumab | 6 | 2021 | 46 | 0.440 |
Why?
| | 4-Aminopyridine | 1 | 2011 | 21 | 0.370 |
Why?
| | Gait Disorders, Neurologic | 1 | 2011 | 41 | 0.360 |
Why?
| | Managed Care Programs | 1 | 2011 | 133 | 0.350 |
Why?
| | Antibodies, Monoclonal | 3 | 2010 | 1257 | 0.340 |
Why?
| | Benchmarking | 1 | 2011 | 161 | 0.340 |
Why?
| | Yellow Fever Vaccine | 1 | 2009 | 6 | 0.330 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 2 | 2021 | 25 | 0.310 |
Why?
| | Telemedicine | 1 | 2016 | 662 | 0.300 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 2 | 2020 | 38 | 0.270 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2012 | 660 | 0.220 |
Why?
| | Smallpox Vaccine | 1 | 2003 | 22 | 0.220 |
Why?
| | Quality of Life | 5 | 2021 | 2343 | 0.190 |
Why?
| | Transcranial Direct Current Stimulation | 1 | 2021 | 4 | 0.190 |
Why?
| | Clinical Trials, Phase IV as Topic | 1 | 2021 | 3 | 0.190 |
Why?
| | Tablets | 1 | 2021 | 36 | 0.180 |
Why?
| | Glatiramer Acetate | 2 | 2019 | 20 | 0.180 |
Why?
| | Motor Disorders | 1 | 2021 | 17 | 0.180 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 90 | 0.180 |
Why?
| | JC Virus | 1 | 2020 | 23 | 0.170 |
Why?
| | Rituximab | 2 | 2019 | 148 | 0.170 |
Why?
| | Cerebellar Diseases | 1 | 2020 | 21 | 0.170 |
Why?
| | Multicenter Studies as Topic | 1 | 2021 | 249 | 0.170 |
Why?
| | Capsid Proteins | 1 | 2020 | 68 | 0.170 |
Why?
| | Administration, Oral | 1 | 2021 | 725 | 0.150 |
Why?
| | Humans | 19 | 2021 | 114045 | 0.150 |
Why?
| | Magnetic Resonance Imaging | 5 | 2021 | 3039 | 0.130 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2016 | 82 | 0.130 |
Why?
| | Brain | 6 | 2021 | 2355 | 0.130 |
Why?
| | Prospective Studies | 2 | 2021 | 6195 | 0.120 |
Why?
| | Bacterial Vaccines | 1 | 2014 | 61 | 0.110 |
Why?
| | Pyridines | 1 | 2016 | 419 | 0.100 |
Why?
| | Viral Vaccines | 1 | 2014 | 88 | 0.100 |
Why?
| | Adjuvants, Immunologic | 1 | 2014 | 206 | 0.100 |
Why?
| | Autoimmune Diseases | 1 | 2015 | 381 | 0.100 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 82 | 0.090 |
Why?
| | Mobility Limitation | 1 | 2011 | 60 | 0.090 |
Why?
| | Nerve Regeneration | 1 | 2010 | 50 | 0.090 |
Why?
| | Autoimmunity | 1 | 2015 | 812 | 0.080 |
Why?
| | Secondary Prevention | 1 | 2010 | 221 | 0.080 |
Why?
| | Disease Progression | 2 | 2016 | 2371 | 0.080 |
Why?
| | Male | 4 | 2021 | 55396 | 0.070 |
Why?
| | Peptides | 1 | 2011 | 847 | 0.060 |
Why?
| | Female | 5 | 2021 | 59324 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2011 | 1381 | 0.050 |
Why?
| | Age Factors | 1 | 2010 | 2885 | 0.050 |
Why?
| | Double-Blind Method | 2 | 2019 | 1656 | 0.050 |
Why?
| | Adult | 5 | 2021 | 30375 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2537 | 0.050 |
Why?
| | Middle Aged | 4 | 2021 | 26605 | 0.050 |
Why?
| | Neurophysiology | 1 | 2021 | 13 | 0.050 |
Why?
| | Atrophy | 1 | 2021 | 152 | 0.050 |
Why?
| | Young Adult | 2 | 2021 | 10444 | 0.050 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2021 | 44 | 0.040 |
Why?
| | Biomarkers | 1 | 2010 | 3397 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2011 | 9049 | 0.040 |
Why?
| | Time Factors | 1 | 2010 | 6077 | 0.040 |
Why?
| | Animals | 3 | 2014 | 31565 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 22 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 56 | 0.040 |
Why?
| | Lower Extremity | 1 | 2021 | 334 | 0.040 |
Why?
| | Risk Factors | 1 | 2010 | 8614 | 0.040 |
Why?
| | Incidence | 1 | 2003 | 2314 | 0.030 |
Why?
| | Diffusion Tensor Imaging | 1 | 2016 | 63 | 0.030 |
Why?
| | B-Lymphocytes | 2 | 2011 | 762 | 0.030 |
Why?
| | United States | 1 | 2011 | 12137 | 0.030 |
Why?
| | Maximum Tolerated Dose | 1 | 2011 | 183 | 0.020 |
Why?
| | Research Design | 1 | 2016 | 919 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2011 | 435 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2012 | 686 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2011 | 1735 | 0.010 |
Why?
| | Adolescent | 1 | 2021 | 17800 | 0.010 |
Why?
| | Aged | 1 | 2020 | 18969 | 0.010 |
Why?
|
|
Miravalle's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|